Ipamorelin Effect on CMP (Comprehensive Metabolic Panel)
How ipamorelin acetate may affect a comprehensive metabolic panel, including glucose, kidney markers, liver enzymes, and electrolytes, and what is and is not established from current evidence.
How ipamorelin acetate may affect a comprehensive metabolic panel, including glucose, kidney markers, liver enzymes, and electrolytes, and what is and is not established from current evidence.
Ipamorelin raises GH levels and can confound GH stimulation test results. Learn the mechanism, expected magnitude of GH rise, washout timing, and monitoring protocols.
Levothyroxine is a T4-only medication, but it can raise Free T3 through peripheral conversion. Learn how Synthroid changes Free T3, what the research shows, and when to test.
How levothyroxine changes Reverse T3 (rT3), what the rise means physiologically, when rT3 testing is actually useful, and why TSH and free T4 remain the primary monitoring targets during treatment.
Does levothyroxine lower or raise TPO antibodies? Review of clinical evidence on Synthroid's effect on thyroid peroxidase antibodies in Hashimoto's thyroiditis, including trial data, timelines, and monitoring recommendations.
Metformin does not directly damage the kidneys, but eGFR determines whether it can be safely prescribed. What the FDA thresholds mean, how monitoring should work, and what remains unproven about kidney protection.
How much will metformin lower A1c in 6 months? Full effect lands by 12 to 16 weeks: about 1.0 to 1.5 percentage points, more if your baseline was high.
Metformin lowers B12 by 10-22% over 1-4 years, with deficiency in 5-10% of long-term users. Learn the mechanism and who needs monitoring.
Tirzepatide (Mounjaro) is expected to lower CGM glucose and raise time in range within weeks of dose escalation. What is established from trial evidence, what needs primary-source verification, and how to adjust CGM monitoring during titration.
Tirzepatide (Mounjaro) can shift multiple CMP markers including fasting glucose, ALT, AST, creatinine, and electrolytes. This article reviews the direction and general magnitude of those changes from published SURPASS trial data, and flags where exact numbers need verification against the primary source.
Learn how Mounjaro (tirzepatide) affects eGFR and kidney function. Review clinical trial data from SURPASS and SURMOUNT programs, monitoring timelines, and what eGFR changes mean for patients on tirzepatide.
Tirzepatide (Mounjaro) lowers fasting plasma glucose by 43 to 65 mg/dL in type 2 diabetes. Learn the mechanism, timeline, trial data from SURPASS-1 through SURPASS-5, and monitoring recommendations.
Tirzepatide (Mounjaro) lowers fasting triglycerides by 19 to 25% in clinical trials. Learn the mechanism, timeline, monitoring schedule, and what the SURPASS data show.
Oral micronized progesterone (Prometrium) raises serum progesterone in a dose-dependent manner. Learn the expected magnitude, time course, monitoring windows, and clinical implications for HRT.
Semaglutide (Ozempic) is expected to lower mean CGM glucose, reduce glycemic variability, and increase time in range in people with type 2 diabetes. Here is what is established, what is plausible but unconfirmed by verified primary sources, and how to read your own CGM data safely.
Ozempic (semaglutide) lowers HbA1c by 1.0 to 1.8 percentage points in clinical trials. Learn the dose-response curve, when to recheck labs, and how it compares to other GLP-1 receptor agonists.
Semaglutide (Ozempic) lowers triglycerides 12-20%, reduces LDL cholesterol, and raises HDL modestly. Learn the magnitude, timeline, and monitoring schedule based on SUSTAIN and SELECT trial data.
How bremelanotide (PT-141) affects 24-hour ambulatory blood pressure, including magnitude of change, time course, mechanism, and clinical monitoring guidance based on RCT data.
Learn how to interpret an ApoB result on rosuvastatin, including trial reductions, differences from LDL-C, repeat testing, and limits of outcome evidence.
What rosuvastatin (Crestor) does to AST liver enzymes, how to tell a muscle-source rise from a liver-source rise, current monitoring practice, and when an AST change on this statin needs urgent follow-up.
Sermorelin acetate stimulates pituitary GH release, raising IGF-1 levels by 15 to 40% over 3 to 6 months. Learn the clinical evidence, expected lab changes, dosing context, and when to recheck IGF-1.
Evidence-based guide to testosterone cypionate's effect on apolipoprotein B (ApoB), including direction of change, magnitude, time course, mechanism, and monitoring recommendations.
Testosterone cypionate raises estradiol levels through aromatization. What is established, what is plausible but unproven, and how sensitive-assay monitoring should be timed and interpreted.
Testosterone cypionate lowers SHBG (sex hormone-binding globulin) by 10 to 30% within weeks of initiation. Learn the mechanism, clinical significance, monitoring schedule, and what declining SHBG means for free testosterone and estradiol.
Wegovy (semaglutide 2.4 mg) is associated with falling ALT levels in most patients treated for obesity, driven by weight loss and liver fat reduction. This article covers what trial evidence establishes, monitoring, red flags, and when ALT changes need workup.
Semaglutide 2.4 mg (Wegovy) typically lowers AST by reducing hepatic fat. Learn the expected magnitude, time course, monitoring schedule, and when AST changes on Wegovy warrant clinical attention.
Wegovy (semaglutide 2.4 mg) changes body composition measurably on DEXA. Here is what happens to fat mass, lean mass, and visceral fat, plus when to scan and how to preserve muscle.
A guide to how Wegovy (semaglutide 2.4 mg) affects estimated glomerular filtration rate (eGFR), including trial data from STEP-1, FLOW, and SELECT, monitoring timelines, and what eGFR changes mean for patients on GLP-1 therapy.
Wegovy (semaglutide 2.4 mg) improves multiple lipid panel markers. Learn the direction, magnitude, and timeline of cholesterol and triglyceride changes backed by STEP trial data.
Tirzepatide (Zepbound) changes body composition on DEXA scans. Learn how much fat vs. Lean mass is lost, when to schedule scans, and how to protect muscle during treatment.
Tirzepatide (Zepbound) significantly reduces visceral adipose tissue. Learn the clinical data on VAT loss magnitude, timeline, mechanisms, and monitoring from SURMOUNT trials.
Finasteride, minoxidil, spironolactone and dutasteride compared by trial data, with dosing, who should avoid each drug, and monitoring schedules.
A guide to inclisiran (Leqvio) food and supplement interactions, covering mechanism of action, known drug-nutrient interactions, and practical dietary guidance for patients on twice-yearly PCSK9 siRNA therapy.
Inclisiran needs just two shots a year after the initial doses, easing adherence for adults 65+ with no added safety risk versus younger patients.
A clinical overview of Leqvio (inclisiran) manufacturing processes, supply chain logistics, shortage history, and current availability status for prescribers and patients.
Leqvio dosing is 284 mg at day 0, month 3, then every 6 months for all adults, including ages 50 to 64. No age-based dose adjustment is specified.
A source-checked look at what is and is not known about inclisiran (Leqvio) safety in pregnancy and breastfeeding, based on FDA labeling, animal reproductive toxicology data, and current lipid-management guidelines.
EMA approved Leqvio (inclisiran) for LDL-C lowering, like the FDA, Health Canada, and NICE, all without proven cardiovascular outcomes data yet.
TRICARE covers Leqvio (inclisiran) for ASCVD and familial hypercholesterolemia with prior authorization. Learn formulary tier, step-therapy requirements, appeal steps, and out-of-pocket costs for military beneficiaries.
The Inflation Reduction Act capped insulin copays at $35/month for Medicare beneficiaries and triggered private-market price cuts. Here is what the IRA insulin cap covers, what it misses, and how to minimize your total diabetes costs in 2026.
Tresiba cuesta $490-540/mes, 2-4 veces más que la glargina biosimilar ($150). DEVOTE mostró 53% menos hipoglucemia nocturna severa que glargina.
Evidence-based guide to managing a missed dose of Tresiba (insulin degludec), including timing rules, clinical pharmacology, and when to contact your provider.
Evidence-based insulin glargine (Lantus) dosing guide for adults aged 30 to 49 with type 1 or type 2 diabetes, including initiation protocols, titration algorithms, and real-world clinical considerations.
Evidence-based guidance on safely tapering or stopping insulin glargine (Lantus), including who qualifies, stepdown protocols, monitoring benchmarks, and when discontinuation is medically inappropriate.
A clinician-grade review of every major drug-drug interaction with insulin glargine (Lantus, Basaglar, Semglee, Toujeo), including hypoglycemia potentiators, hyperglycemic antagonists, and masking agents.
Evidence-based guide to insulin glargine (Lantus) dosing in adults 65 and older, covering starting doses, titration, hypoglycemia risk, renal adjustments, and deprescribing strategies.
Insulin glargine's A21 glycine and B31-B32 arginine modifications shift the isoelectric point to pH 6.7, causing microprecipitation at physiologic pH 7.4.
Evidence-based protocol for handling missed doses of insulin glargine (Lantus), including timing thresholds, hypoglycemia risk, and when to contact your prescriber.
Does Lantus need refrigerating? Yes: unopened vials and pens keep at 36 to 46 °F until expiry date. Once opened, store at room temp and toss in 28 days.
A clinical review of the drug interaction between Adderall XR (mixed amphetamine salts) and atorvastatin, covering CYP metabolism, cardiovascular monitoring, and dose-adjustment guidance.
Adderall and birth control: no clinically significant interaction. Amphetamines don't reduce contraceptive efficacy; monitor blood pressure and heart rate.
Board-reviewed analysis of the Adderall XR (mixed amphetamine salts) and finasteride drug interaction, covering CYP metabolism, shared side effects, cardiovascular monitoring, and practical prescribing guidance.
Omeprazole raises stomach pH, so Adderall XR's delayed-release beads dissolve early. That means a higher peak and a shorter duration. Here's what to know.
A pharmacology-based review of the Adderall XR (mixed amphetamine salts) and pregabalin combination, covering mechanism, monitoring, dose timing, and where the evidence runs out.
Clinical guide to combining Adderall XR (mixed amphetamine salts) with SSRIs like sertraline or escitalopram. Covers serotonin syndrome risk, CYP2D6 interactions, dose adjustments, and monitoring.
Board-reviewed guide to the mixed amphetamine salts (Adderall XR) and tadalafil drug interaction, covering mechanism, severity, monitoring parameters, and dose-adjustment strategies.
Board-reviewed guide to the Adderall XR (mixed amphetamine salts) and testosterone interaction. Covers pharmacokinetic overlap, polycythemia risk, cardiovascular monitoring, and dose-adjustment considerations.
Can you take alendronate (Fosamax) with ibuprofen or naproxen? What is established, what is plausible, and what remains unverified about the combined GI and renal risk.
Clinical analysis of the alendronate (Fosamax) and rosuvastatin drug interaction, including pharmacokinetic mechanisms, muscle risk, dosing separation, and monitoring guidance.
Board-reviewed guide to the alendronate (Fosamax) and sildenafil interaction. Covers pharmacokinetics, CYP metabolism, timing rules, monitoring, and patient counseling.